A novel protocol to derive cervical motor neurons from induced pluripotent stem cells for amyotrophic lateral sclerosis

Stem Cell Reports. 2023 Sep 12;18(9):1870-1883. doi: 10.1016/j.stemcr.2023.07.004. Epub 2023 Aug 17.

Abstract

Sporadic amyotrophic lateral sclerosis (sALS) is the majority of ALS, and the lack of appropriate disease models has hindered its research. Induced pluripotent stem cell (iPSC) technology now permits derivation of iPSCs from somatic cells of sALS patients to investigate disease phenotypes and mechanisms. Most existing differentiation protocols are time-consuming or low efficient in generating motor neurons (MNs). Here we report a rapid and simple protocol to differentiate MNs in monolayer culture using small molecules, which led to nearly pure neural stem cells in 6 days, robust OLIG2+ pMNs (73%-91%) in 12 days, enriched CHAT+ cervical spinal MNs (sMNs) (88%-97%) in 18 days, and functionally mature sMNs in 28 days. This simple and reproducible protocol permitted the identification of hyperexcitability phenotypes in our sALS iPSC-derived sMNs, and its application in neurodegenerative diseases should facilitate in vitro disease modeling, drug screening, and the development of cell therapy.

Keywords: Amyotrophic Lateral Sclerosis; Calcium imaging; Multielectrode array; Notch pathway; Spinal Motor Neuron Differentiation; Whole-Cell Patch-Clamp; induced Pluripotent Stem Cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis*
  • Autophagy
  • Cell Differentiation
  • Humans
  • Induced Pluripotent Stem Cells*
  • Motor Neurons
  • Osteochondrodysplasias*